

## Total Synthesis of Agelagalastatin


Yong Joo Lee, Bo-Young Lee, Heung Bae Jeon, and Kwan Soo Kim\*

Center for Bioactive Molecular Hybrids and Department of Chemistry,  
Yonsei University, Seoul 120-749, Korea

kwan@yonsei.ac.kr

Received June 13, 2006

## ABSTRACT



The total synthesis of agelagalastatin, an antineoplastic glycosphingolipid, has been achieved. The synthesis involved an  $\alpha$ -selective glycosylation of the ceramide moiety with the trisaccharide fluoride. The trisaccharide component was constructed employing the CB glycoside method which permitted a completely  $\alpha$ -stereoselective galactofuranosylation.

Agelagalastatin (**1**) was isolated from the Western Pacific marine sponge *Agelas* sp., and its structure was elucidated in 1991.<sup>1</sup> This compound is a member of a family of glycosphingolipids found in *Agelas* sp. which include agelasphin-9b,<sup>2</sup> longiside,<sup>3</sup> triglycosylceramide,<sup>4</sup> and KRN7000.<sup>5</sup> These glycosphingolipids, which commonly contain  $\alpha$ -O-galactopyranosyl ceramide moieties as their integral parts, have shown immunomodulating activity.<sup>5,6</sup> Among them, agelasphin-9b and KRN7000 exhibited immunostimulatory activity, which was suggested to be related to the interesting in vivo antitumoral properties of these compounds through an activation of the immune system,<sup>2,7</sup> and thus, KRN7000 is in clinical trials as a novel anticancer agent.<sup>8</sup> Agelagal-

astatin (**1**) displayed significant in vitro inhibitory activities against human cancer cell growth, its GI<sub>50</sub> values ranging from 0.77  $\mu$ g/mL for lung NCI-H460 to 2.8  $\mu$ g/mL for the ovarian OVCAR-3.<sup>1</sup> Besides its biological activity, the unique structure of **1** has attracted our attention as it is composed of two galactofuranosides having  $\alpha$ - and  $\beta$ -glycosyl linkages and a galactopyranoside having an  $\alpha$ -glycosyl linkage with ceramide, as shown in structure **1**. The galactofuranoside moiety with  $\alpha$ -configuration is quite rare in Nature and has been found only in a few microorganisms such as *Penicillium varians*,<sup>9</sup> *Leishmania major*,<sup>10</sup> and *Talaromyces flavus*.<sup>11</sup> In addition, agelagalastatin (**1**) was isolated as a mixture of two structural isomers (**1a/1b** = 4:1) in very low yield (7.42  $\times$  10<sup>-6</sup>%) because of the difficulty in separation.<sup>1</sup> Herein, we describe the first total synthesis of pure **1a** and **1b**.

Retrosynthesis of the target compound **1** leads to three galactoside building blocks **5–7** and a ceramide moiety **3** (Scheme 1). For the successful synthesis of **1**, it is essential to choose efficient glycosylation methods. Particularly challenging is its  $\alpha$ -galactofuranosyl moiety, which is often a

(1) Pettit, G. R.; Xu, J.-p.; Gingrich, D. E.; Williams, M. D.; Doubek, D. L.; Chapius, J.-C.; Schmidt, J. M. *Chem. Commun.* **1999**, 915.

(2) Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y. *Tetrahedron* **1994**, *50*, 2771.

(3) Cafieri, F.; Fattorusso, E.; Mahajnah, Y.; Mangoni, A. *Leibigs Ann. Chem.* **1994**, 1187.

(4) Costantino, V.; Fattorusso, E.; Mangoni, A.; Akin, M.; Gaydon, E. M. *Leibigs Ann. Chem.* **1994**, 1181.

(5) Costantino, V.; Fattorusso, E.; Mangoni, A. *Tetrahedron* **1996**, *52*, 1573.

(6) D'Ambrosio, M.; Ripamonti, M.; Debitus, C.; Waikedre, J.; Pietra, F. *Helv. Chim. Acta* **1996**, *79*, 727.

(7) Motoki, K.; Kobayashi, E.; Uchida, T.; Fukushima, H.; Koezuka, Y. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 705.


(8) Crul, M.; Mathôt, R. A. A.; Giaccone, G.; Punt, C. J. A.; Rosing, H.; Hillebrand, M. J. X.; Ando, Y.; Nishi, N.; Tanaka, H.; Schellens, J. H. M.; Beijnen, J. H. *Cancer Chemother. Pharmacol.* **2002**, *49*, 287.

(9) Jansson, P.-E.; Lindberg, B. *Carbohydr. Res.* **1980**, *82*, 97.

(10) McConville, M. J.; Homans, S. W.; Thomas-Oates, J. E.; Dell, A.; Bacic, A. *J. Biol. Chem.* **1990**, *265*, 7385.

(11) Parra, E.; Jiménez-Barbero, J.; Bernabé, M.; Leal, J. A.; Prieto, A.; Gómez-Miranda, B. *Carbohydr. Res.* **1994**, *251*, 315.

**Scheme 1.** Retrosynthesis of Agelagalastatin **1**




problematic subunit to incorporate stereoselectively. Attention needs to be paid to coupling the four building blocks, **3** and **5–7**, in the proper and correct order. The stereospecific construction of 1,2-*cis*  $\alpha$ -galactofuranosyl and  $\alpha$ -galactopyranosyl linkages has been one of the great challenges of D-glycoside synthesis.<sup>12</sup> In particular, there are no reliable methods available for the stereospecific synthesis of  $\alpha$ -galactofuranosides, although a few attempts have been made employing galactofuranosyl trichloroacetimidates<sup>13</sup> and thio-galactofuranosides<sup>14</sup> as glycosyl donors. Our original plan was to employ 2'-carboxybenzyl (CB) glycosides as glycosyl donors<sup>15</sup> for the coupling of all four components of **1**. We envisioned that the construction of the  $\alpha$ -galactopyranosyl linkage of **1** could be carried out by coupling between CB trisaccharide **2** and the ceramide moiety **3** in the later stages. We also believed that the crucial  $\alpha$ -galactofuranosylation might be possible in the reaction between CB galactofuranoside **5** and 2'-(benzyloxycarbonyl)benzyl (BCB) disaccharide **4**, which would be readily obtainable from **6** and **7**.

Our synthesis commenced with the preparation of three building blocks **5–7** starting from D-galactose: compounds **5** and **6** were prepared via peracetylgalactofuranose **8**<sup>16</sup> as shown in Scheme 2 and compound **7** via 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-galactopyranosyl bromide (see the Supporting Information).

Anomeric chlorination of **8** followed by coupling of the resulting crude galactosyl chloride and benzyl 2-hydroxymethylbenzoate (**18**) afforded BCB tetraacetylgalactoside **9**. After conversion of **9** to **10** by deacetylation, the tetrol **10** was subjected to *O*-benzylation. Subsequent selective hydrogenolysis of the benzyl ester functionality<sup>15</sup> in the resultant

**Scheme 2.** Preparation of Monosaccharide Building Blocks **5** and **6**



BCB benzylgalactoside **11** thereafter provided the building block **5**. Protection of **10** with dimethoxypropane, on the other hand, gave the 5,6-*O*-isopropylidene derivative **12** and the subsequent protection of the diol **12** with TBDMSCl afforded the desired 2-*O*-silyl ether **13** along with a small amount of 3-*O*-silyl ether **14** (**13/14** = 10:1) in 90% yield. *O*-Benzylation of **13** followed by *O*-desilylation of the resulting **15** with  $\text{Bu}_4\text{NF}$  gave alcohol **16**. After *O*-pivaloylation of **16**, the resultant BCB galactoside **17** was converted into the building block **6**. Attempts to directly convert **12** into **17** by selective *O*-pivaloylation of the diol **12** by using PivCl in the presence of pyridine at 0 °C resulted in the formation of a mixture of 2-*O*-, 3-*O*- and 2,3-di-*O*-pivaloyl compounds.

To evaluate the exact reaction conditions needed and appropriate structures for glycosyl donors and acceptors in the crucial  $\alpha$ -galactofuranosylation, we carried out a model study on the reaction of the donor **5** with the simpler acceptor **16** in the place of the disaccharide acceptor **4**. The model study began with dropwise addition of a diluted solution of  $\text{Ti}_2\text{O}$  in  $\text{CH}_2\text{Cl}_2$  to a solution of **5**, **16**, and 2,6-di-*tert*-butyl-4-methylpyridine (DTBMP) in  $\text{CH}_2\text{Cl}_2$  at  $-78$  °C to afford the desired  $\alpha$ -disaccharide **19** exclusively in 68% yield along with self-condensed ester **20**, which probably resulted from coupling between the carboxylate anion and the oxocarbenium ion generated from **5**, in 24% yield (method A in Scheme 3). To suppress formation of the ester **20**, the glycosylation was carried out with reversal of the order of the addition of reactants such that the concentration of **5** could be kept to a minimum during the glycosylation. Thus, slow addition of the donor **5** to a solution of acceptor **16**, DTBMP, and  $\text{Ti}_2\text{O}$  in  $\text{CH}_2\text{Cl}_2$  at  $-78$  °C afforded only the  $\alpha$ -galactosyl disaccharide **19** in 82% yield (method B). The stereochemistry at the newly generated anomeric center of the disaccharide **19** was determined on the basis of its  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data, especially the  $\text{H1}'\text{--H2}'$  coupling constant ( $J_{\text{H1}'\text{--H2}'} = 4.5$  Hz) and the  $\text{C1}'$  chemical shift ( $\delta_{\text{C1}'}$  99.0).<sup>14</sup>

(12) For a review on 1,2-*cis*-glycosylation, see: Demchenko, A. V. *Synlett* **2003**, 1225.


(13) Gelin, M.; Ferrières, V.; Plusquellec, D. *Carbohydr. Lett.* **1997**, *2*, 381.

(14) Gelin, M.; Ferrières, V.; Plusquellec, D. *Eur. J. Org. Chem.* **2000**, 1423.

(15) (a) Kim, K. S.; Kim, J. H.; Lee, Y. J.; Lee, Y. J.; Park, J. J. *Am. Chem. Soc.* **2001**, *123*, 8477. (b) Kim, K. S.; Park, J.; Lee, Y. J.; Seo, Y. S. *Angew. Chem., Int. Ed.* **2003**, *42*, 459. (c) Kim, K. S.; Kang, S. S.; Seo, Y. S.; Kim, H. J.; Lee, Y. J.; Jeong, K.-S. *Synlett* **2003**, 1311. (d) Kwon, Y. T.; Lee, Y. J.; Lee, K.; Kim, K. S. *Org. Lett.* **2004**, *6*, 3901. (e) Lee, Y. J.; Lee, K.; Jung, E. H.; Jeon, H. B.; Kim, K. S. *Org. Lett.* **2005**, *7*, 3263.


(16) Ferrières, V.; Gelin, M.; Boulch, R.; Toupet, L.; Plusquellec, D. *Carbohydr. Res.* **1998**, *314*, 79.

**Scheme 3.** Glycosylation of **16** with **5** for  $\alpha$ -Galactofuranosylation



With this promising result for the  $\alpha$ -galactofuranosylation with **5**, the stage was set for the assembly of building blocks **5**–**7** to make the trisaccharide **2** (Scheme 4). Glycosylation

**Scheme 4.** Preparation of Trisaccharide Glycosyl Donor **2**




of **7** with **6** was carried out under the conditions of method B to give the  $\beta$ -disaccharide **21** exclusively in 79% yield. Removal of the *O*-pivaloyl group from **21** with NaOBn gave the alcohol **4**. Then, the crucial  $\alpha$ -galactofuranosylation of the acceptor **4** with the donor **5** was successfully executed under the conditions of method B to afford the desired  $\alpha$ -galactofuranosyl trisaccharide **22** ( $J_{\text{H1}'-\text{H2}'}$  = 4.6 Hz and  $\delta_{\text{C1}'}$  98.5) exclusively in 91% yield. No  $\beta$ -trisaccharide was detected at all in the reaction mixture. The BCB trisaccharide **22** was converted into the CB trisaccharide **2** by selective hydrogenolysis. It is noteworthy that the reaction of the CB galactofuranoside **5** with the disaccharide **4** provided only the  $\alpha$ -trisaccharide **22** in excellent yield, which is the first example of a completely stereoselective  $\alpha$ -galactofuranosylation.

Our approach to the synthesis of ceramides **3a** and **3b** made use of the olefin cross-metathesis reaction to install the main carbon chain. Recently, the cross-metathesis olefination for the synthesis of sphingosines has become attractive due to the high *E*-selectivity and good yield of the

process and its wide functional group tolerance.<sup>17</sup> Wittig reaction of known D-lyxose derivative **23**<sup>18</sup> with ylide  $\text{CH}_2=\text{PPh}_3$  gave olefin **24**. The olefin cross-metathesis of **24** with 11-methyldodec-1-ene (**39**) and with 12-methyltridec-1-ene (**40**) in the presence of Grubbs' catalyst **41**<sup>19</sup> in refluxing  $\text{CH}_2\text{Cl}_2$  provided the desired *trans*-olefins **25** and **26** in 75% and 76% yields, respectively (Scheme 5). After hydrogenation

**Scheme 5.** Preparation of Ceramides **3a** and **3b** and Their Glycosylations with CB Trisaccharide **2**



tion of **25**, the hydroxy group in **27** was activated as an *O*-triflate, and this subjected to an  $\text{S}_{\text{N}}2$  reaction with tetramethylguanidinium azide (TMGA)<sup>20</sup> to give azido compound **29** with inverted configuration. Removal of the *O*-isopropylidene group of **29** by trifluoroacetic acid (TFA) followed by benzylation of the resulting diol afforded

(17) (a) Torssell, S.; Somfai, P. *Org. Biomol. Chem.* **2004**, *2*, 1643. (b) Rai, A. N.; Basu, A. *Org. Lett.* **2004**, *6*, 2861. (c) Rai, A. N.; Basu, A. *J. Org. Chem.* **2005**, *70*, 8228. (d) Chaudhari, V. D.; Ajish Kumar, K. S.; Dhavale, D. D. *Org. Lett.* **2005**, *7*, 5805.

(18) Cheng, X.; Khan, N.; Mootoo, D. R. *J. Org. Chem.* **2000**, *65*, 2544.

(19) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. *Org. Lett.* **1999**, *1*, 953.

(20) Tuch, A.; Sanière, M.; Merrer, Y. L.; Depeyaz, J.-C. *Tetrahedron: Asymmetry* **1996**, *7*, 897.


compound **31** which, after hydrogenolysis, gave amine **33**. The homologue of **33**, compound **34**, was readily obtained in a like fashion from **26**. Coupling reaction of **33** with (*R*)-2-acetoxypentacosanoic acid (**35**) using 2-ethoxy-1-ethoxy-carbonyl-1,2-dihydroquinoline (EEDQ)<sup>21</sup> afforded amide **37**, and same reaction of **34** with (*R*)-2-acetoxytetracosanoic acid (**36**) provided amide **38**. Finally, a desilylation of **37** and **38** with Bu<sub>4</sub>NF gave alcohols **3a** and **3b**, respectively.

Glycosylation of the ceramide **3a** with the CB trisaccharide **2** afforded the desired protected agelagalastatin **42a $\alpha$**  ( $\delta_{C1}$  100.6) in 45% yield, along with undesired  $\beta$ -anomer **42a $\beta$**  ( $\delta_{C1}$  104.5) in 32% yield, and the reaction of ceramide **3b** with **2** also gave a mixture of  $\alpha$ - and  $\beta$ -anomers **42b** with the same ratio ( $\alpha/\beta = 1.4:1$ ) in 75% yield. Poor stereoselectivity in the glycosylation of **3** with the CB glycoside **2** led us to examine other glycosyl donors that could be readily prepared from **2**. We envisaged that sequential treatment of the CB glycoside **2** with Tf<sub>2</sub>O and then with a fluoride reagent would give the glycosyl fluoride. Reaction of **2** with Tf<sub>2</sub>O and then with (diethylamino)sulfur trifluoride (DAST) as a fluoride source afforded a mixture of  $\alpha$ - and  $\beta$ -glycosyl fluoride **43** in 48% yield, whereas the same reaction with hydrogen fluoride pyridine as a fluoride source was quite efficient giving **43** in 83% ( $\beta/\alpha = 20:1$ ) yield (Scheme 6).

Glycosylations of **3a** and **3b** with **43** as the glycosyl donor were carried out by dropwise addition of a solution of **43** in THF to a solution of acceptor **3a** or **3b**, SnCl<sub>2</sub>, AgClO<sub>4</sub>,<sup>22</sup> and DTBMP in THF at -10 °C to afford desired  $\alpha$ -glycosides **42a $\alpha$**  and **42b $\alpha$**  exclusively in 72% and 73% yield, respectively. The deprotection of **42a $\alpha$**  started with removal of the *O*-benzylidene and *O*-isopropylidene groups using TFA and was followed by hydrogenolysis to remove the benzyl groups. Finally, the *O*-acetyl and *O*-benzoyl protecting groups were removed using sodium methoxide in MeOH and CH<sub>2</sub>Cl<sub>2</sub> to give the target compound **1a**. The other target compound **1b** was obtained from **42b $\alpha$**  by the same deprotection sequence under the same reaction conditions.

The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the authentic agelagalastatin isolated by Pettit and of our synthetic agelagalastatin (**1**) were identical in all respects.<sup>23</sup> Also, the optical rotations of synthetic compounds **1a** and **1b** were measured to be  $[\alpha]_D +58.8$  (*c* 0.65, CH<sub>3</sub>OH) and  $[\alpha]_D +59.8$  (*c* 0.45, CH<sub>3</sub>OH), respectively, which is exactly matched with the reported value of  $[\alpha]_D +59$  (*c* 0.65, CH<sub>3</sub>OH) for the authentic agelagalastatin, which is a mixture of **1a** and **1b** with a ratio of 4:1.

We have thus achieved the first total synthesis of both the major component **1a** and the minor component **1b** of agelagalastatin (**1**). For the construction of the trisaccharide moiety **2**, we made use of the CB glycoside method.



Particularly, the glycosylation of **4** with the CB galactofuranoside **5** showed complete  $\alpha$ -stereoselectivity, giving only the  $\alpha$ -galactofuranosyl trisaccharide **22**. On the other hand, for the coupling of the trisaccharide moiety and the ceramide part, trisaccharyl fluoride **43** was utilized as the glycosyl donor to afford  $\alpha$ -glycosides **42a $\alpha$**  and **42b $\alpha$**  exclusively. For the synthesis of ceramides **3a** and **3b**, we employed olefin cross metathesis to install the main carbon chain efficiently. The biological activity of each component of agelagalastatin, **1a** and **1b**, will be reported in a separate communication.

**Acknowledgment.** This work was supported by a grant from the Korea Science and Engineering Foundation through Center for Bioactive Molecular Hybrids (CBMH). We also thank to Professor G. R. Pettit (Arizona State University) for providing copies of the NMR spectra of the natural agelagalastatin.

**Supporting Information Available:** Experimental procedures and characterization data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL061444O

(21) Belleau, B.; Malek, G. *J. Am. Chem. Soc.* **1968**, *90*, 1651.  
 (22) For SnCl<sub>2</sub>/AgClO<sub>4</sub> as the promoter for glycosyl fluoride, see: Mukaiyama, T.; Murai, Y.; Shoda, S. *Chem. Lett.* **1981**, 431.  
 (23) See the Supporting Information.